To further define the nature of the cell-cell interaction required to elicit an increase in endothelial [Ca"+j, two cell types that lack the 82 integrin were studied. In experiments similar to those described above, freshly isolated red blood cells (n=5) or suspensions of cultured human aortic endothelial cells (not loaded with indo 1, n=8) were perfused through the capillary tube containing the endothelial monolayer and allowed to contact the monolayer under "no-flow" conditions. Before being perfused through the capillary tube containing the endothelial monolayer, endothelial cells were nonenzymatically detached from tissue culture dishes using 1 mmol/L EGTA for 20 minutes Schroeder et a137 recently reported that the Ca21 channel blocker diltiazem inhibited the development of coronary artery disease in heart transplant recipients, a process that may be initiated by interaction of circulating lymphocytes and the vascular endothelium of the transplanted heart. Ca21 channel blockers have also been shown to inhibit LDL-stimulated formation of InsP3 in human lymphocytes,38 which may in turn have an effect on ER Ca'+ release. The mechanism of the inhibition of PMN adhesion and chemotaxis by Ca21 channel antagonists31,32 is incompletely understood, but these studies in combination suggest that Ca 2+ antagonists may well have effects on intracellular Ca2+ homeostasis in leukocytes in addition to their well-known effects on Ca 2+ channels in other cell types. Thus, pharmacological manipulation of leukocyte or endothelial [Ca2+] in situations in which leukocyte adhesion and subsequent leukocyte-mediated injury are likely to occur, such as following coronary angioplasty or reperfusion of ischemic myocardium, may provide a novel therapeutic strategy in the treatment of cardiovascular disease.
